Top Stock Picks for Investors on December 30th
Here are three stocks with a buy rank and strong momentum characteristics for investors to consider today, December 30th:
CoreCard Corporation: A Strong Performer in Technology Solutions
CoreCard Corporation (CCRD): This technology solutions and processing services company holds a Zacks Rank #1. The Zacks Consensus Estimate for its current year earnings has increased by 7% in the last 60 days.
CoreCard Corporation Price and Consensus
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
Over the last three months, CoreCard shares surged by 44.9%, compared to the S&P 500’s gain of 5.3%. The company also holds a Momentum Score of A.
CoreCard Corporation Price
CoreCard Corporation price | CoreCard Corporation Quote
Entrada Therapeutics: Boosted Earnings Outlook
Entrada Therapeutics, Inc. (TRDA): This clinical-stage biotechnology company also has a Zacks Rank #1. The Zacks Consensus Estimate for its current year earnings has jumped by 64.7% over the past 60 days.
Entrada Therapeutics, Inc. Price and Consensus
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
Entrada’s shares increased by 8.8% over the last three months, outperforming the S&P 500 which gained 5.3%. It too holds a Momentum Score of A.
Entrada Therapeutics, Inc. Price
Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals: Significant Earnings Growth
NRx Pharmaceuticals, Inc. (NRXP): This clinical-stage biotechnology company also holds a Zacks Rank #1. The Zacks Consensus Estimate for its current year earnings has risen by 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
Recently, NRx’s stock rose by 11.8% in the past month, while the S&P 500 saw a slight decline of 0.7%. The company has a Momentum Score of A.
NRx Pharmaceuticals, Inc. Price
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here.
Learn more about the Momentum score and how it is calculated here.
Discover Zacks’ Top 10 Stocks for 2025
Interested in early access to our 10 top picks for 2025?
Historical performance indicates that these stocks could excel.
Since 2012, under the guidance of Sheraz Mian, the Zacks Top 10 Stocks portfolio gained +2,112.6%, significantly outperforming the S&P 500’s +475.6%. Sheraz is reviewing 4,400 companies to select the best 10 candidates for 2025. Stay tuned for these stock picks coming January 2.
Be First to New Top 10 Stocks >>
NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report
Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report
CoreCard Corporation (CCRD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
